Thomas Walsh is an Antifungal resistance and susceptibility physician affiliated with Cornell University. OpenAlex indexes 1,015 publications with 105,956 citations (h-index 141); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Infectious Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Thomas Walsh, M.D., is affiliated with Cornell University. The public record shows 1,015 publications with 105,956 citations (h-index 141), centered on Antifungal resistance and susceptibility, Fungal Infections and Studies, Infectious Diseases and Mycology. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 5 companies.
- Most recent indexed publication: 2025 · Antimicrobial agents and chemotherapy
- Top research focus: Antifungal resistance and susceptibility
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 715.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Can A Virtual Clinic Review Replace A Surgical Clinic Visit After Discharge?
Sponsor: Connolly Hospital Blanchardstown
- Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Sponsor: Enzon Pharmaceuticals, Inc.
- A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
Sponsor: Enzon Pharmaceuticals, Inc.
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202511 payments$19,445openpaymentsdata.cms.gov ↗
- Associates of Cape Cod IncorporatedProgram year20251 payment
- Abbott LaboratoriesProgram year202430 payments$51,408openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Azole Antifungal100%Ketoconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective.
Antimicrobial agents and chemotherapy
Article2025 - Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology.
Journal of clinical microbiology
Review2024 - Development of rabbit models of ventilator-associated bacterial pneumonia produced by carbapenem-resistant Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy
Article2024 - Reply to Kidd et al., "Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion".
Journal of clinical microbiology
Letter2024
Most-cited works
by citation count (OpenAlex)- 02
- 03
- 04Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesArticle3,038 citations2005
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
news.weill.cornell.edu/people/dr-thomas-walsh
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.weill.cornell.edu ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Devereux, MD
Cornell University
Cora Sternberg, MD
Cornell University
George Alexopoulos, MD
Cornell University
James Bussel, MD
Cornell University